Concerns with the new SYNTAX score

Affiliations

¹ University College London, London WC1V 6LJ, UK. Electronic address: nicholas.freemantle@ucl.ac.uk.
² European Association for Cardio-Thoracic Surgery, Windsor, UK.

Comment

Nick Freemantle et al. Lancet. 2021.

. 2021 Feb 27;397(10276):795.

doi: 10.1016/S0140-6736(21)00223-3.

¹ University College London, London WC1V 6LJ, UK. Electronic address: nicholas.freemantle@ucl.ac.uk.
² European Association for Cardio-Thoracic Surgery, Windsor, UK.

No abstract available

Comment in

Concerns with the new SYNTAX score - Authors' reply.
Takahashi K, van Klaveren D, Steyerberg EW, Onuma Y, Serruys PW. Takahashi K, et al. Lancet. 2021 Feb 27;397(10276):795-796. doi: 10.1016/S0140-6736(21)00195-1. Lancet. 2021. PMID: 33640065 No abstract available.

Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation.
Takahashi K, Serruys PW, Fuster V, Farkouh ME, Spertus JA, Cohen DJ, Park SJ, Park DW, Ahn JM, Kappetein AP, Head SJ, Thuijs DJ, Onuma Y, Kent DM, Steyerberg EW, van Klaveren D; SYNTAXES, FREEDOM, BEST, and PRECOMBAT trial investigators. Takahashi K, et al. Lancet. 2020 Oct 31;396(10260):1399-1412. doi: 10.1016/S0140-6736(20)32114-0. Epub 2020 Oct 8. Lancet. 2020. PMID: 33038944 Clinical Trial.